JOURNAL ARTICLE
Add like
Add dislike
Add to saved papers

Assessment of the Effectiveness of Percutaneous Transluminal Balloon Angioplasty for Failing or Nonmaturing Arteriovenous Fistulae for Hemodialysis.

BACKGROUND: Autologous arteriovenous (A-V) fistulae are the recommended arteriovenous access for long-term dialysis in chronic renal failure patients. However, the rate of nonmaturity and failure is still significant. The present study aimed at salvaging fistulas using percutaneous transluminal balloon angioplasty (PTA).

METHODS: Thirty-two patients with nonmaturing or failing fistulas were included, to which they were subjected to PTA with preintervention and postintervention fistulograms to assess the success rate in restoring the fistulae's patency and function.

RESULTS: Salvage rate was 26 of 32 fistulas (81.3%) in which the fistulas regain their usability for hemodialysis at least for 3 months of follow-up, 4 cases (12.5%) persist nonmature and 2 cases (6.3%) were not used for stenosis.

CONCLUSIONS: PTA is a safe and effective method for treating nonmature and failing native A-V fistulas.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app